Not sure, but my PP shares are held by Cleartrust not a broker. After a year I could transfer them to a broker, actually 6 months but that incurs fees.
Considering all the new assets and patents the Company acquired it is strange that it trades this low. The only negative news was a NIH trial failure as a monotherapy with a patient population of 18 despite roughly 3.5 yrs of enrollment. The average patient had an average of about 9 years of chronic depression and it doesn’t appear any drug has been successful with that population. Just a guess, but I doubt the Company would have even done that trial
Had they been made aware of the extreme patient population. Still waiting for the full data from that trial as it has not been released.
As I am sure you are aware J&J’s esketamine and AXSM drug have done well . Esketamine was approved as an adjunctive and AXSM has phase 2 success as an adjunctive. AXSM struggled in the $2 range and had similar financing struggles at times like VTGN had. Based mainly on the positive phase 2 depression trial AXSM moved from 2 to 26 in less than 6 months. They have other drugs in their portfolio as well
VTGN switched its trial to adjunctive over 2 years ago. The patient population is double what AXSM is.
I like the chances of success and if you look back at the charts you will see some spikes of 300 percent or more on heavy volume. My crystal ball is shattered as to predicting pps but if VTGN has phase 2 success on AV101 for depression I can see this in the 20’s. They also have a nasal depression, AV101 non opioid pain indications and a fast acting nasal anxiety drug through phase 2.
I guess it would make everyone feel better if the stock was 1.5 to 2 but if you were not going to be a seller at those levels this is certainly a unique opportunity.
If the trial is not a success obviously we are headed south.
News 
Market Data 
Discover 
